Analyst Research Report Snapshot

Title:

AB SCIENCE - IMPROVING MASITINIB OUTLOOK

Price:

$10.00

Provider:

Edison Investment Research

Date:

06 Feb 2012

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ABS.PA

Available for Immediate Download
Summary:

AB Science’s (AB) investment case is dependent on the successful development of masitinib. Impressive Phase II results showing that the tyrosine kinase inhibitor (TKI) beat Pfizer’s Sutent in extending overall survival in Gleevec-resistant gastrointestinal stromal tumours (GIST) has sparked a 100% share price gain. AB is conducting eight Phase III trials of masitinib so expectations are likely to rise for further positive data, particularly in first-line GIST and pancreatic cancer; the latter trial provides another major inflection point when it reads out in April 2012.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.